evipedia.aidev
← Back

High-Dose Vitamin C to Treat Cancer

Evidence Review created on 08/11/2026 using AI4L / Grok 4

Also known as: Intravenous Vitamin C, IVC, Pharmacologic Ascorbate, Pharmacological Ascorbate, High-Dose Ascorbic Acid, Mega-Dose Vitamin C

Motivation

High-dose vitamin C is ascorbic acid given far above ordinary nutritional needs, most often by intravenous infusion so blood levels rise far higher than diet or ordinary oral medication can achieve. At those levels it can act as a pro-oxidant, generating hydrogen peroxide that preferentially stresses cancer cells while normal tissues remain relatively protected. Interest among health- and longevity-oriented adults comes from adding a well-tolerated agent to standard cancer care, easing symptoms, and—in selected settings—supporting longer survival.

The idea grew from mid-century clinical observations and work by Linus Pauling and Ewan Cameron, then faded after oral-only randomized trials were negative. Later absorption work showed oral dosing cannot produce plasma levels needed for pro-oxidant effects, renewing intravenous study. Current trials and reviews are mixed: safety is generally favorable after screening, quality-of-life gains appear in several studies, a small pancreatic trial reported longer survival, and larger trials have not confirmed broad benefit.

This review examines evidence for and against high-dose vitamin C as a cancer treatment or add-on—mechanisms, history, benefits and risks, interactions, protocols, monitoring, and emerging research—so risk-aware adults can weigh data with conventional care.

Benefits - Risks - Protocol - Conclusion

Curated high-level overviews and expert discussions of pharmacologic vitamin C in oncology.

Priority-source note: No substantial Huberman Lab episode or article was found that addresses high-dose vitamin C for cancer by name in depth. Lifespan.io and Chris Kresser searches returned only incidental mentions, not dedicated high-level overviews.

Grokipedia

  • Vitamin C megadosage

    Covers Pauling-era claims, oral-versus-intravenous (IV) pharmacokinetics, contemporary oncology and sepsis trials, and the shift from megadose oral supplementation to pharmacologic intravenous use.

Examine

  • Vitamin C

    Examine monograph on vitamin C with research breakdowns that include anti-cancer mechanisms, IV infusion studies, and practical dosing context for supplemental forms.

ConsumerLab

  • Vitamin C Supplements Review

    Independent testing of oral vitamin C products, form comparisons, upper-intake cautions (oxalate, cataracts), and clinical-update links relevant when oral maintenance accompanies IV protocols.

Systematic Reviews

Systematic reviews and meta-analyses assessing intravenous or high-dose vitamin C in people with cancer.

Mechanism of Action

At nutritional intakes, vitamin C (ascorbic acid) is mainly a water-soluble antioxidant and enzyme cofactor. Intravenous gram-scale doses raise plasma levels from the micromolar into the millimolar range—levels oral dosing cannot sustain because absorption and renal reabsorption are tightly controlled (Padayatty et al., 2004).

In extracellular fluid, millimolar ascorbate can reduce transition metals and generate hydrogen peroxide (H₂O₂). Many cancer cells clear peroxide poorly and are more vulnerable than normal cells (Chen et al., 2005). Downstream effects include DNA damage, ATP (cellular energy currency) depletion, activation of ATM (a DNA-damage sensor) and AMPK (a cellular energy sensor), and inhibition of mTOR (a growth-signaling hub), leading to cell death. High ascorbate may also boost TET (ten-eleven translocation) dioxygenases that demethylate DNA, an epigenetic path of interest in some blood cancers.

Pharmacologically, ascorbate is water-soluble, distributes mainly into extracellular water, and is cleared by the kidneys with an elimination half-life of about 2 hours after high-dose infusion; it is not a major cytochrome P450 (CYP450) substrate. Selectivity is imperfect: red cells lacking G6PD cannot make enough NADPH (a reducing cofactor for oxidative defense) and are vulnerable. A competing view is that continuous low-dose oral antioxidants might blunt some ROS (reactive oxygen species)–dependent therapies—a concern that does not clearly apply to brief millimolar IV peaks.

Historical Context & Evolution

Vitamin C entered cancer care in the 1950s–1970s through clinical observations that large parenteral doses sometimes improved well-being and, in uncontrolled series by Cameron and Pauling, appeared to lengthen survival in advanced disease. Those reports used intravenous ascorbic acid followed by oral maintenance and lacked modern randomization. Two Mayo Clinic randomized trials in the late 1970s and mid-1980s (Creagan et al., 1979; Moertel et al., 1985) tested high-dose oral vitamin C only and found no survival benefit, leading mainstream oncology to abandon the approach.

The modern revival rests on pharmacokinetic clarification. Work from Mark Levine’s group at the NIH showed that oral dosing is tightly controlled (peak plasma roughly 200 µmol/L even at multi-gram oral intakes), whereas intravenous infusion can produce 10–20 mmol/L peaks—the range in which selective cancer-cell killing is observed in vitro. This explained why oral-only RCTs could not test the pharmacologic hypothesis. Subsequent phase I trials established safety of doses up to about 1.5 g/kg after G6PD and renal screening, and phase II work explored combinations with chemotherapy and radiation. Integrative clinics (e.g., Riordan protocol) continued empirical use. Opinion has shifted from “disproven by Mayo” to “unproven at pharmacologic IV doses; under active trial,” with both supportive small RCTs and null larger trials now coexisting in the literature.

Expected Benefits

Medium 🟩 🟩

Improved quality of life and reduced chemotherapy toxicity

Studies report better quality of life (QoL), less fatigue, and fewer grade 1–2 toxicities when high-dose IV vitamin C is added to chemotherapy. In a randomized ovarian-cancer trial, twice-weekly 75–100 g ascorbate with carboplatin/paclitaxel reduced multi-organ toxicities without shortening progression time (Ma et al., 2014). Reviews note consistent QoL signals despite heterogeneous designs (Fritz et al., 2014; van Gorkom et al., 2019).

Magnitude: Grade 1–2 chemotherapy toxicities reduced across multiple organ systems in the Ma ovarian trial; QoL score improvements reported in several series (exact instruments vary).

Longer overall survival as adjunct in metastatic pancreatic cancer

A randomized phase II trial in stage IV pancreatic ductal adenocarcinoma compared gemcitabine plus nab-paclitaxel alone versus the same regimen plus pharmacologic ascorbate 75 g three times weekly. Median overall survival (OS) was 16.0 versus 8.3 months (hazard ratio (HR) 0.46; 90% confidence interval (CI) 0.23–0.92), with progression-free survival (PFS) 6.2 versus 3.9 months, without added toxicity (Bodeker et al., 2024; NCT02905578). Sample size was small (34 treated); confirmatory trials are needed.

Magnitude: Median OS roughly doubled (16.0 vs 8.3 months; HR 0.46) in one randomized phase II trial (n = 34 treated).

Low 🟩

Progression-free survival benefit restricted to RAS (growth-signal gene family)–mutant metastatic colorectal cancer

The VITALITY trial (n = 442) of vitamin C plus FOLFOX (folinic acid, fluorouracil, oxaliplatin) ± bevacizumab did not improve PFS or OS. A RAS-mutant subgroup had longer PFS (9.2 vs 7.8 months; HR 0.67) (Wang et al., 2022).

Magnitude: PFS +1.4 months (HR 0.67) in RAS-mutant subgroup only; overall trial null for PFS/OS.

Symptom relief (fatigue, nausea, insomnia, mood)

Uncontrolled series and the Fritz systematic review associate IV vitamin C with reductions in cancer- or chemotherapy-related fatigue, nausea, insomnia, constipation, and depression. Randomized confirmation is sparse; effects may partly reflect repletion of common deficiency in advanced cancer rather than pure pharmacologic action.

Magnitude: Not quantified in available studies.

Speculative 🟨

Direct tumor regression as monotherapy

Case reports describe responses or long disease-free intervals with high-dose IV vitamin C alone. No modern randomized monotherapy trial confirms tumor-shrinkage rates comparable to standard agents.

Synergy with metabolic interventions (e.g., fasting-mimicking diet, ketosis)

Preclinical and early translational work (including discussion in longevity-medicine forums) suggests combining pharmacologic ascorbate with nutrient-restriction or glutamine-targeting strategies may amplify stress on KRAS-driven tumors. Human outcome data are not available.

Benefit-Modifying Factors

  • Tumor genotype (KRAS/BRAF/RAS pathway): RAS-mutant colorectal cancer showed a PFS signal in VITALITY; KRAS- and BRAF-driven models (related cancer-driver genes) are often more ascorbate-sensitive in vitro. Wild-type tumors may derive less direct cytotoxic benefit.

  • Baseline vitamin C status: Advanced cancer frequently coexists with low plasma ascorbate; repletion may improve symptoms and immune competence even before pharmacologic peaks are reached.

  • Route and achieved plasma level: Only IV dosing reliably produces millimolar peaks; oral megadoses remain sub-pharmacologic for cytotoxicity and should not be expected to match IV trial results.

  • Combination with concurrent chemotherapy/radiation: Most positive signals appear in combination regimens (pancreas, ovary); monotherapy evidence is weaker. Timing relative to ROS-dependent agents matters for mechanism alignment.

  • Age and performance status: Older adults and those with poorer performance status may gain more from toxicity-sparing and QoL effects; frailty and polypharmacy raise monitoring needs.

  • Sex: No consistent sex-specific efficacy differences have been established for pharmacologic ascorbate in cancer trials; enrollment has often been disease-specific rather than sex-stratified for interaction testing.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency

High-dose IV vitamin C can precipitate acute intravascular hemolysis (red-cell destruction) in people with G6PD deficiency because red cells cannot regenerate enough NADPH to defend against peroxide stress. Cases including life-threatening hemolysis after ~80 g infusions are documented. Universal pre-screening is standard in oncology protocols (NCI PDQ; Alangari et al., 2026).

Magnitude: Rare in screened populations; potentially severe or fatal when G6PD deficiency is missed.

Oxalate nephropathy and acute kidney injury

Ascorbate is metabolized in part to oxalate. High IV loads can raise urinary oxalate and, in susceptible individuals (pre-existing renal impairment, dehydration, history of calcium-oxalate stones), cause acute oxalate nephropathy or stone formation. Case reports include renal failure after large doses in patients with compromised kidney function.

Magnitude: Uncommon with screening and hydration; risk rises sharply with estimated glomerular filtration rate (eGFR) impairment or prior oxalate stone disease.

Medium 🟥 🟥

During and shortly after multi-gram infusions, thirst, polyuria, temporary blood-pressure changes, lightheadedness, and vein irritation or phlebitis can occur. These are usually self-limited and related to osmolar load and volume. Electrolyte shifts (e.g., sodium from sodium ascorbate formulations) require attention in susceptible patients.

Magnitude: Common mild symptoms in high-dose series; severe events uncommon when infusion rate and fluid balance are controlled.

Laboratory assay interference

High plasma ascorbate can falsely elevate or lower readings on certain point-of-care glucose meters and may interfere with some stool occult-blood and other assays. Clinical decisions based on fingerstick glucose during or soon after infusion can be wrong.

Magnitude: Device-dependent; recognized in product labeling and trial protocols; not a direct tissue toxicity.

Low 🟥

Gastrointestinal symptoms (mainly oral high-dose)

Oral doses above roughly 2 g often cause osmotic diarrhea, nausea, and abdominal cramping (basis of the 2,000 mg/day Tolerable Upper Intake Level for adults). IV dosing bypasses the gut, so these effects are far less prominent unless oral maintenance is co-administered at high doses.

Magnitude: Common above 2 g oral; infrequent with IV-only protocols.

Possible antagonism with specific agents (e.g., bortezomib)

Preclinical and limited clinical data suggest ascorbic acid can reduce the activity of the proteasome inhibitor bortezomib. This is a drug-specific concern rather than a class-wide chemotherapy antagonism; many other agents have been co-administered without clear loss of efficacy.

Magnitude: Documented for bortezomib; not generalized to all cytotoxics in clinical combination trials.

Speculative 🟨

Theoretical blunting of ROS-dependent therapy by low-dose antioxidants

Oral antioxidants during chemo or radiation link to worse cancer outcomes (Ambrosone et al., 2020). Whether brief IV peaks act the same is uncertain; protocols target pro-oxidant peaks, not continuous exposure.

Risk-Modifying Factors

  • G6PD genotype/phenotype: Deficiency (more prevalent in African, Mediterranean, Middle Eastern, and some Asian ancestries) is the dominant risk amplifier for hemolysis; quantitative enzyme assay before first high-dose infusion is standard.

  • Baseline renal function and stone history: Reduced eGFR, dehydration, or prior calcium-oxalate stones increase oxalate nephropathy risk; adequate hydration and renal clearance checks modify risk downward.

  • Formulation and infusion rate: Hyperosmolar solutions and rapid infusion increase vein irritation and hemodynamic effects; sodium ascorbate versus ascorbic acid changes sodium load.

  • Age and comorbidity: Older adults with reduced renal reserve, heart failure, or multiple nephrotoxic drugs need tighter fluid and electrolyte monitoring.

  • Sex: G6PD deficiency is X-linked and clinically more often severe in males; no major sex difference in oxalate risk is established beyond stone epidemiology.

Key Interactions & Contraindications

  • Bortezomib (proteasome inhibitor): Caution — ascorbic acid may antagonize antitumor activity; avoid concurrent high-dose vitamin C unless in a supervised protocol designed for that combination.

  • Other ROS-dependent chemotherapies/radiation: Monitor — theoretical concern that continuous oral antioxidants could blunt efficacy; brief IV pharmacologic peaks have been co-administered with gemcitabine, platinum agents, taxanes, and radiation in trials without clear loss of benefit.

  • Iron supplements / iron overload (hemochromatosis): Caution — vitamin C enhances non-heme iron absorption and can worsen iron-mediated oxidative injury; separate oral iron and use care in overload states.

  • Nephrotoxic drugs (e.g., high-dose nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen; aminoglycosides such as gentamicin): Caution — additive kidney stress when oxalate load is high; ensure hydration and renal monitoring.

  • Point-of-care glucose meters: Monitor — spurious glucose readings during/after infusion; prefer laboratory plasma glucose if glycemic decisions are needed.

  • Oral anticoagulant / antiplatelet regimens: Monitor — high-dose vitamin C has had mixed reports on warfarin; check INR (international normalized ratio, a clotting-time measure) if clinically indicated when starting large IV loads.

Populations who should avoid High-Dose Vitamin C:

  • Known G6PD deficiency (absolute for high-dose IV)
  • Significant renal impairment or active calcium-oxalate stone disease without specialist clearance
  • Uncorrected dehydration or anuria
  • Known allergy to ascorbate formulation components
  • Concurrent bortezomib unless under a trial protocol that addresses the interaction

Risk Mitigation Strategies

  • Mandatory G6PD screening: Quantitative enzyme assay before the first high-dose IV infusion to prevent hemolysis.

  • Renal function and hydration gate: Check creatinine/eGFR and urinalysis; ensure adequate IV/oral hydration and ability to void before multi-gram infusions to reduce oxalate nephropathy risk.

  • Start-low titration: Begin with a lower test dose (e.g., 15 g in many integrative protocols) before escalating to 50–100 g or 1–1.5 g/kg to catch intolerance or infusion reactions early.

  • Controlled infusion rate and osmolarity: Use appropriate diluent volume and infusion duration (often 1–2+ hours) to limit phlebitis and hemodynamic swings.

  • Hold oral megadose antioxidants around ROS-based therapy days: Prefer protocolized IV peaks over continuous high-dose oral antioxidants during active radiation or certain chemotherapies when the care team is concerned about antagonism.

  • Device-aware glucose monitoring: Do not rely on susceptible fingerstick meters during or immediately after high-dose infusion; use laboratory assays when decisions depend on glucose.

Therapeutic Protocol

  • Pharmacologic IV adjunct (trial-style): 75 g IV thrice weekly with chemo (e.g., pancreas NCT02905578), or 1.5 g/kg/day for 3 days per cycle (VITALITY); phase I supports up to ~1.5 g/kg after screening.

  • Integrative / Riordan-style protocol: Gradual escalation from ~15 g toward multi-gram doses (often 25–100 g) 2–3 times weekly, with oral multi-form vitamin C on non-infusion days; continuous schedules emphasized by originating clinics.

  • Combination versus monotherapy: Leading academic approaches almost always pair IV ascorbate with standard chemotherapy or chemoradiation rather than using it as sole antitumor therapy.

  • Time of day: No strong circadian requirement; infusions are typically scheduled in clinic daytime hours for monitoring. Avoid combining them immediately before unreliable fingerstick glucose checks.

  • Half-life and dosing split: Elimination half-life after high-dose IV is ~2 hours; multi-hour infusions and multi-day-per-week schedules are used to re-establish millimolar peaks rather than continuous steady state.

  • Oral maintenance (optional adjunct): Some protocols add divided oral ascorbate or liposomal forms on non-IV days to limit trough deficiency; oral doses do not replace IV for pharmacologic peaks.

  • Genetics: Screen G6PD before first high dose. KRAS/RAS mutation status may inform expectations for cytotoxic synergy but does not currently define a universal dose change.

  • Sex and age: No standard sex-based dose split; older adults need stricter renal and volume assessment. Body-weight or body-surface-area dosing (g/kg or g/m²) is preferred over fixed grams in academic protocols.

  • Baseline status: Correct dehydration and document renal function and G6PD before escalation; consider baseline plasma ascorbate if deficiency is suspected.

Discontinuation & Cycling

  • Duration of use: In oncology trials, IV ascorbate is usually continued for a defined course concurrent with chemotherapy (weeks to months) or until progression/intolerance—not as an indefinite lifelong primary cancer therapy.

  • Withdrawal effects: No classic withdrawal syndrome is described; plasma levels fall quickly (hours) after the last infusion because of short half-life and renal clearance.

  • Tapering: Formal tapers are uncommon; infusions are simply stopped or stepped down when the concurrent anticancer regimen ends or goals of care change.

  • Cycling: Some integrative practices use ongoing twice-weekly infusions for months; others cycle with chemo blocks. No evidence that drug holidays restore efficacy in the way hormone or kinase-inhibitor holidays sometimes do.

  • Restart considerations: Repeat renal and clinical assessment before restarting after a long gap; G6PD need not be retested if previously normal and no new hemolytic trigger is suspected.

Sourcing and Quality

  • Pharmaceutical-grade injectables: Sterile ascorbic acid or sodium ascorbate for injection from compounding pharmacies or commercial sterile manufacturers; USP-grade raw materials and sterile compounding standards are essential.

  • What to look for: Clear labeling of ascorbate form and amount, appropriate diluent compatibility, endotoxin/sterility testing, and avoidance of multi-dose vials that have been mishandled. Preservative-free formulations are typical for large IV loads.

  • Reputable channels: Hospital pharmacies, 503A/503B compounding pharmacies experienced with high-dose ascorbate, and clinical-trial supply chains. Wellness-spa “Myers cocktail” products are not equivalent to oncology pharmacologic dosing.

  • Oral products (maintenance only): For oral components, third-party testing (USP, NSF, or labs such as ConsumerLab) for identity and label claim reduces under- or over-potency risk; form (ascorbic acid vs mineral ascorbates vs liposomal) is secondary to dose and GI (gastrointestinal) tolerance.

Practical Considerations

  • Time to effect: Symptom/QoL changes are sometimes reported within days to a few weeks of regular infusions. Survival or progression endpoints, where present, emerge over months of concurrent therapy.

  • Common pitfalls: Using oral megadoses and expecting IV-trial results; skipping G6PD or renal screens; relying on fingerstick glucose during infusion; equating spa intravenous vitamin infusions with pharmacologic oncology protocols; stopping indicated chemotherapy in favor of ascorbate monotherapy outside a trial.

  • Regulatory status: Ascorbic acid injectables are available, but high-dose IV vitamin C is not FDA-approved as a cancer treatment; oncology use is off-label or investigational. Cost is usually out-of-pocket and can be substantial for multi-gram, multi-week courses.

  • Access and logistics: Requires IV access, clinic time (often 1–2+ hours per infusion), and a clinician experienced with screening and monitoring; travel burden is a real constraint for thrice-weekly regimens.

Interaction with Foundational Habits

  • Sleep: Direct effects are minimal. Reduced pain, nausea, or anxiety when QoL improves may indirectly support sleep; evening large infusions could increase nocturia from osmotic diuresis.

  • Nutrition: Correcting vitamin C deficiency supports collagen and immune function. High IV doses raise oxalate generation—adequate fluid intake and not overdoing ultra-high oxalate diets matter for stone-prone individuals. Oral iron should be timed separately. Metabolic diets (e.g., fasting-mimicking) are under study as potential synergists, not requirements.

  • Exercise: No established blunting of training adaptations unique to intermittent IV pharmacologic peaks (unlike some chronic high-dose oral antioxidant studies). Fatigue reduction could support activity; schedule demanding exercise away from long infusion days if energy dips post-treatment.

  • Stress management: Indirect—improved physical symptoms may ease psychological load. No direct cortisol pathway effect is established for high-dose ascorbate in cancer care.

Monitoring Protocol & Defining Success

Before starting high-dose IV vitamin C, establish G6PD status, renal function, hydration, and relevant cancer baselines (imaging, tumor markers, performance status, and symptom scores). During therapy, recheck renal function and electrolytes on a schedule matched to infusion intensity, watch for hemolysis symptoms after the first doses, and track cancer outcomes with the treating oncology team. Success in the adjunctive setting is typically defined as maintained or improved quality of life, acceptable toxicity, and—where relevant—stable or improved disease metrics without compromising standard therapy.

Ongoing cadence commonly used in practice: laboratories at baseline, after the first one to two high-dose infusions, then every two to four weeks during continuous twice- or thrice-weekly therapy, and with each chemotherapy cycle when combined. Imaging and tumor markers follow the oncology schedule (often every two to three months).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
G6PD enzyme activity Within lab normal (deficient = avoid high-dose IV) Prevent hemolysis Once before first high-dose infusion; quantitative assay preferred
Creatinine / eGFR Stable near personal baseline; avoid if significantly reduced without specialist input Oxalate/renal risk Baseline, then periodically (e.g., every 2–4 weeks during intensive IV)
Serum electrolytes (Na, K) Within lab normal Osmotic/sodium load from formulations Baseline and with renal panels during escalation
Complete blood count Stable; watch Hb/Hct drop Detect hemolysis or chemo toxicity Hb/Hct = hemoglobin/hematocrit; baseline; early after first high doses; per oncology schedule
Plasma ascorbate (optional) Deficiency correction: ≥50 µmol/L; pharmacologic peaks measured only in research settings Confirm repletion / research PK PK = pharmacokinetics; not required for every clinical course; peaks are transient (~2 h half-life)
Tumor markers / imaging Per oncology plan Disease control Parallel to standard cancer monitoring, not replaced by ascorbate labs
Point-of-care glucose Use lab plasma if decision-critical around infusion Meter interference Avoid relying solely on susceptible fingerstick devices during/after IV

Qualitative markers:

  • Energy and fatigue scores (e.g., simple 0–10 scale or FACT (Functional Assessment of Cancer Therapy) subscales)
  • Nausea, appetite, and sleep quality
  • Pain and overall well-being / performance status
  • Ability to complete planned chemotherapy without dose-limiting toxicity

Emerging Research

  • Metastatic pancreatic cancer survival signal: Randomized phase II data (Bodeker et al., 2024; NCT02905578) showed roughly doubled median OS with 75 g ascorbate thrice weekly plus standard chemo; larger confirmatory trials would strengthen or refute this finding.

  • Null or mixed solid-tumor RCTs: VITALITY in metastatic colorectal cancer was negative for PFS/OS (RAS-mutant subgroup positive) (Wang et al., 2022); IV vitamin C plus docetaxel in castration-resistant prostate cancer was futile (Paller et al., 2024).

  • Ongoing combination trials: Non-small cell lung cancer chemoradiation plus ascorbate (phase II, n≈43; NCT02905591); glioblastoma plus ferumoxytol (phase I, n≈16; NCT04900792); lymphoma (phase II, n≈80; NCT03418038); acute myeloid leukemia plus azacitidine/venetoclax (phase I, n≈30; NCT07177079).

  • Meta-analytic survival signal: Qu et al., 2025 reported longer median OS with IV vitamin C across heterogeneous studies (moderate certainty); sensitivity to study design and region was noted, so more homogeneous large RCTs remain decisive.

  • Mechanistic refinement: Work on KRAS-selective vulnerability, TET-mediated epigenetic reprogramming, and iron-catalyzed peroxide generation may identify biomarkers that separate responders from non-responders and clarify when ascorbate helps versus when it does not.

Conclusion

High-dose vitamin C for cancer is best understood as a high-dose, usually intravenous, add-on rather than a nutritional supplement or proven standalone cure. Very high plasma levels—achievable only by infusion—can generate hydrogen peroxide and stress many cancer cells while leaving most normal tissues relatively intact. After screening for a red-cell enzyme deficiency (G6PD) and adequate kidney function, multi-gram infusions have a generally favorable short-term safety record in clinical series and trials.

The benefit picture is uneven. Quality-of-life and chemotherapy-toxicity improvements appear across several studies and are among the more reproducible findings. A small randomized trial in metastatic pancreatic cancer reported substantially longer survival when vitamin C was added to standard chemotherapy, and a large colorectal trial suggested a progression-free survival edge limited to tumors with common growth-signal gene mutations (the RAS family). In contrast, overall results in that colorectal trial and a placebo-controlled prostate trial were not positive, and older systematic reviews judged antitumor evidence as low quality. Pooled analyses report longer average survival with intravenous vitamin C, but certainty remains moderate.

For a risk-aware adult engaged with conventional oncology care, the evidence supports viewing high-dose intravenous vitamin C as an experimental add-on with plausible mechanisms, manageable risks when screened, and disease-specific signals—not as a replacement for standard therapy. Oral megadoses do not reproduce intravenous trial blood levels. Cost, infusion logistics, and the incomplete large-trial picture remain material constraints.

Top - Benefits - Risks - Protocol